Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
24 01 2019
Historique:
pubmed: 12 12 2018
medline: 29 10 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Human murine double minute 2 (MDM2) protein is a primary endogenous cellular inhibitor of the tumor suppressor p53 and has been pursued as an attractive cancer therapeutic target. Several potent, nonpeptide, small-molecule inhibitors of MDM2 are currently in clinical development. In this paper, we report our design, synthesis, and evaluation of small-molecule MDM2 degraders based on the proteolysis targeting chimera (PROTAC) concept. The most promising compound (MD-224) effectively induces rapid degradation of MDM2 at concentrations <1 nM in human leukemia cells. It achieves an IC

Identifiants

pubmed: 30525597
doi: 10.1021/acs.jmedchem.8b00909
pmc: PMC6545112
mid: NIHMS1020015
doi:

Substances chimiques

4-(6''-chloro-4'-(3-chloro-2-fluorophenyl)-2''-oxodispiro(cyclohexane-1,2'-pyrrolidine-3',3''-indoline)-5'-carboxamido)benzoic acid 0
Apoptosis Regulatory Proteins 0
BBC3 protein, human 0
Indoles 0
Proto-Oncogene Proteins 0
Spiro Compounds 0
Tumor Suppressor Protein p53 0
Proto-Oncogene Proteins c-mdm2 EC 2.3.2.27

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

448-466

Subventions

Organisme : NCI NIH HHS
ID : P30 CA046592
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA208267
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219345
Pays : United States

Références

J Med Chem. 2018 Jan 25;61(2):462-481
pubmed: 28339196
Mol Med. 1999 Feb;5(2):71-83
pubmed: 10203572
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):7124-9
pubmed: 27274052
Pharmacol Ther. 2017 Jun;174:138-144
pubmed: 28223226
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10
pubmed: 26593377
ACS Med Chem Lett. 2013 Apr 02;4(5):466-9
pubmed: 24900694
Adv Cancer Res. 2000;77:81-137
pubmed: 10549356
Nat Rev Cancer. 2013 Feb;13(2):83-96
pubmed: 23303139
J Med Chem. 2017 Apr 13;60(7):2819-2839
pubmed: 28339198
Science. 2015 Jun 19;348(6241):1376-81
pubmed: 25999370
J Med Chem. 2015 Feb 12;58(3):1038-52
pubmed: 25396320
J Med Chem. 2016 Jun 9;59(11):5129-30
pubmed: 27199030
J Med Chem. 2015 Aug 27;58(16):6348-58
pubmed: 26181851
Nature. 2014 Aug 7;512(7512):49-53
pubmed: 25043012
Nat Rev Cancer. 2009 Dec;9(12):862-73
pubmed: 19935675
J Med Chem. 2014 Feb 27;57(4):1454-72
pubmed: 24456472
Science. 2004 Feb 6;303(5659):844-8
pubmed: 14704432
Cancer Res. 2017 May 1;77(9):2476-2487
pubmed: 28209615
Angew Chem Int Ed Engl. 2017 May 15;56(21):5738-5743
pubmed: 28418626
J Med Chem. 2013 Jul 25;56(14):5979-83
pubmed: 23808545
Chem Commun (Camb). 2017 Jul 4;53(54):7577-7580
pubmed: 28636052
Cell. 1992 Jun 26;69(7):1237-45
pubmed: 1535557
Nat Rev Cancer. 2007 Mar;7(3):165-8
pubmed: 17332760
Cancer Res. 2014 Oct 15;74(20):5855-65
pubmed: 25145672
Cell Mol Life Sci. 1999 Jan;55(1):96-107
pubmed: 10065155
Nat Chem Biol. 2015 Aug;11(8):611-7
pubmed: 26075522
ACS Chem Biol. 2015 Aug 21;10(8):1770-7
pubmed: 26035625
Sci Rep. 2018 Jan 22;8(1):1294
pubmed: 29358579
Genes Dev. 1993 Jul;7(7A):1126-32
pubmed: 8319905
Chem Biol. 2015 Jun 18;22(6):755-63
pubmed: 26051217
Bioorg Med Chem Lett. 2016 Oct 15;26(20):4865-4869
pubmed: 27666635

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH